awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33754036-FA7EAD3A-D111-45ED-A625-4F61F8272611
Q33754036-FA7EAD3A-D111-45ED-A625-4F61F8272611
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754036-FA7EAD3A-D111-45ED-A625-4F61F8272611
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.
P2860
Q33754036-FA7EAD3A-D111-45ED-A625-4F61F8272611
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754036-FA7EAD3A-D111-45ED-A625-4F61F8272611
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fe7f7703ed20cb49c4031eb5d44908ca90928574
P2860
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.